Back to Search
Start Over
CTLA-4 Blockade Resistance after Relatlimab and Nivolumab.
- Source :
-
The New England journal of medicine [N Engl J Med] 2022 Apr 28; Vol. 386 (17), pp. 1668-1669. - Publication Year :
- 2022
- Subjects :
- Antibodies, Monoclonal adverse effects
Antibodies, Monoclonal therapeutic use
Antineoplastic Agents, Immunological adverse effects
Antineoplastic Agents, Immunological therapeutic use
Drug Resistance, Neoplasm
Humans
Immune Checkpoint Inhibitors adverse effects
Immune Checkpoint Inhibitors therapeutic use
Antibodies, Monoclonal, Humanized adverse effects
Antibodies, Monoclonal, Humanized therapeutic use
CTLA-4 Antigen antagonists & inhibitors
Drug Resistance
Nivolumab adverse effects
Nivolumab therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1533-4406
- Volume :
- 386
- Issue :
- 17
- Database :
- MEDLINE
- Journal :
- The New England journal of medicine
- Publication Type :
- Editorial & Opinion
- Accession number :
- 35476655
- Full Text :
- https://doi.org/10.1056/NEJMc2119768